Please wait while we load the requested 10-K report or click the link below:
TYME Announces Fourth Quarter and Fiscal Year 2020 Financial and Operating Results
TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer
PanCAN enrolling patients in its Precision PromiseSM adaptive randomized Phase II/III registration-intent trial evaluating oral SM-88 as second-line monotherapy for pancreatic cancer
TYME & Joseph Ahmed Foundations HopES sarcoma study enrolling patients for the investigator-initiated Phase II trial studying oral SM-88 as maintenance monotherapy in previously treated metastatic Ewings sarcoma and salvage monotherapy in clinically advanced sarcomas
TYME to present updated findings from preclinical data on cancer metabolism-based compounds: SM-88 and TYME-18
Strategic collaboration with Eagle Pharmaceuticals entitled TYME to receive up to a total of $40 million, which included $20 million upfront and $20 million in potential milestone payments
Additional capital resources better position TYME to carry out its clinical trials in pancreatic cancer and sarcomas, advance plans for clinical trials in metastatic breast, prostate and/or hematological cancers, as well as continue developing pre-clinical and mechanism data studies
Fourth Quarter and Fiscal Year 2020 conference call today, May 20th, at 5 p.m. Eastern Standard Time
NEW YORK, NY, May 20, 2020 (BUSINESS NEWSWIRE) Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced preliminary financial and operating results for its fourth quarter and fiscal year ended March 31, 2020. TYME delivered on multiple major milestones in Fiscal Year 2020, including its two most important corporate priorities, launching the first pivotal trial that will evaluate oral SM-88 (racemetyrosine) for patients with third-line pancreatic cancer and strengthening its capital structure. Given these developments, TYME now has a clear path toward becoming a commercial enterprise.
During fiscal 2020, the Company presented a growing body of clinical data at major international medical meetings, initiated the TYME pivotal study in third-line pancreatic cancer, partnered with PanCAN to initiate the Precision PromiseSM Phase II/III registration intent study in second-line pancreatic cancer, and expanded the clinical study program
The following information was filed by Tyme Technologies, Inc. (TYME) on Wednesday, May 20, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Tyme Technologies, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Tyme Technologies, Inc..